Article

InSite Vision launches enhanced Web site

Alameda, CA-InSite Vision Inc. announces it has launched an enhanced company Web site at www.insitevision.com. The new Web site includes descriptions of the company's corporate strategy, technology platforms, and product portfolio to serve the medical and investment communities better. In addition, the site will provide the media with 24-hour access to news and information about ophthalmic therapeutics, diagnostics, and drug-delivery systems that are available from the company.

Alameda, CA-InSite Vision Inc. announces it has launched an enhanced company Web site at http://www.insitevision.com/ . The new Web site includes descriptions of the company's corporate strategy, technology platforms, and product portfolio to serve the medical and investment communities better. In addition, the site will provide the media with 24-hour access to news and information about ophthalmic therapeutics, diagnostics, and drug-delivery systems that are available from the company.

The Web site includes key content and graphic material to assist in educating visitors about the company and its products.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.